Bloomage Biotechnology Corp Stock Fundamentals

688363 Stock   59.16  1.32  2.28%   
Bloomage Biotechnology Corp fundamentals help investors to digest information that contributes to Bloomage Biotechnology's financial success or failures. It also enables traders to predict the movement of Bloomage Stock. The fundamental analysis module provides a way to measure Bloomage Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bloomage Biotechnology stock.
At present, Bloomage Biotechnology's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 6.3 B, whereas Net Income Applicable To Common Shares is forecasted to decline to about 562.4 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bloomage Biotechnology Corp Company Current Valuation Analysis

Bloomage Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Bloomage Biotechnology Current Valuation

    
  28.26 B  
Most of Bloomage Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bloomage Biotechnology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Bloomage Biotechnology Corp has a Current Valuation of 28.26 B. This is 147.66% higher than that of the Chemicals sector and 8.28% lower than that of the Materials industry. The current valuation for all China stocks is 69.97% lower than that of the firm.

Bloomage Biotechnology Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bloomage Biotechnology's current stock value. Our valuation model uses many indicators to compare Bloomage Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bloomage Biotechnology competition to find correlations between indicators driving Bloomage Biotechnology's intrinsic value. More Info.
Bloomage Biotechnology Corp is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers reporting about  0.51  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Bloomage Biotechnology Corp is roughly  1.94 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bloomage Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bloomage Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Bloomage Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bloomage Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bloomage Biotechnology could also be used in its relative valuation, which is a method of valuing Bloomage Biotechnology by comparing valuation metrics of similar companies.
Bloomage Biotechnology is currently under evaluation in current valuation category among its peers.

Bloomage Fundamentals

About Bloomage Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bloomage Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bloomage Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bloomage Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue6.1 B3.4 B
Cost Of Revenue1.6 B1.7 B

Currently Active Assets on Macroaxis

Other Information on Investing in Bloomage Stock

Bloomage Biotechnology financial ratios help investors to determine whether Bloomage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bloomage with respect to the benefits of owning Bloomage Biotechnology security.